Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase II Trial of Induction Chemotherapy Followed by Cetuximab (Erbitux) With Low Dose vs. Standard Dose IMRT in Patients With HPV-Associated Resectable Squamous Cell Carcinoma of the Oropharynx
Brief Summary: RATIONALE: Drugs used in chemotherapy, such as paclitaxel and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Radiation therapy uses high energy x-rays to kill tumor cells. Giving paclitaxel, cisplatin, and cetuximab together with radiation therapy may kill more tumor cells.

PURPOSE: This phase II trial is studying paclitaxel, cisplatin, and cetuximab to see how well they work when followed by cetuximab and two different doses of intensity-modulated radiation therapy in treating patients with HPV-associated stage III or stage IV cancer of the oropharynx that can be removed by surgery.


Options:
A: Arm Label: Cetuximab Plus Chemotherapy; Type: EXPERIMENTAL; Interventions: Drug: Cetuximab + Platinum (Cisplatin or Carboplatin) + 5Fluorouracil (5-FU) | Arm Label: Chemotherapy alone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Platinum (Cisplatin or Carboplatin) + 5-FU | Intervention Type: DRUG; Name: Cetuximab + Platinum (Cisplatin or Carboplatin) + 5Fluorouracil (5-FU); Assigned to Arm(s): Cetuximab Plus Chemotherapy | Intervention Type: DRUG; Name: Platinum (Cisplatin or Carboplatin) + 5-FU; Assigned to Arm(s): Chemotherapy alone
B: Arm Label: Arm I; Type: EXPERIMENTAL; Interventions: Drug: carboplatin, Drug: cisplatin, Drug: docetaxel, Drug: fluorouracil | Arm Label: Arm II; Type: EXPERIMENTAL; Interventions: Drug: cisplatin | Intervention Type: DRUG; Name: carboplatin; Assigned to Arm(s): Arm I | Intervention Type: DRUG; Name: cisplatin; Assigned to Arm(s): Arm I, Arm II | Intervention Type: DRUG; Name: docetaxel; Assigned to Arm(s): Arm I | Intervention Type: DRUG; Name: fluorouracil; Assigned to Arm(s): Arm I
C: Arm Label: Group 1; Type: EXPERIMENTAL; Interventions: Biological: cetuximab, Radiation: intensity-modulated radiation therapy (IMRT), Drug: Paclitaxel, Drug: Cisplatin | Arm Label: Group 2; Type: EXPERIMENTAL; Interventions: Biological: cetuximab, Radiation: intensity-modulated radiation therapy (IMRT), Drug: Paclitaxel, Drug: Cisplatin | Intervention Type: BIOLOGICAL; Name: cetuximab; Assigned to Arm(s): Group 1, Group 2 | Intervention Type: RADIATION; Name: intensity-modulated radiation therapy (IMRT); Assigned to Arm(s): Group 1, Group 2 | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Group 1, Group 2 | Intervention Type: DRUG; Name: Cisplatin; Assigned to Arm(s): Group 1, Group 2
D: Arm Label: Standard fractionation RT + cisplatin; Type: OTHER; Interventions: Drug: cisplatin, Radiation: Standard fractionation RT, Procedure: Conventional surgery for select patients | Arm Label: Accelerated fractionation RT + cisplatin; Type: EXPERIMENTAL; Interventions: Drug: cisplatin, Radiation: Accelerated fractionation radiation therapy, Procedure: Conventional surgery for select patients | Intervention Type: DRUG; Name: cisplatin; Assigned to Arm(s): Accelerated fractionation RT + cisplatin, Standard fractionation RT + cisplatin | Intervention Type: RADIATION; Name: Standard fractionation RT; Assigned to Arm(s): Standard fractionation RT + cisplatin | Intervention Type: RADIATION; Name: Accelerated fractionation radiation therapy; Assigned to Arm(s): Accelerated fractionation RT + cisplatin | Intervention Type: PROCEDURE; Name: Conventional surgery for select patients; Assigned to Arm(s): Accelerated fractionation RT + cisplatin, Standard fractionation RT + cisplatin

Answer: C